Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Special Issue "Breast Cancer: From Pathophysiology to Novel Therapies".

International journal of molecular sciences·2026

Same author

Contour and dosimetric evaluation of an in-room mobile CBCT scanner for cylinder based brachytherapy.

Brachytherapy·2026

Same author

FOLR1-targeted actinium-225-based alpha-particle therapy eliminates ovarian cancer.

Science advances·2026

Same author

Contribution of the glossopharyngeal nerve in imidapril-mediated enhancement of the swallowing reflex in rats.

Journal of oral biosciences·2026

Same author

American Brachytherapy Society consensus guidelines for medical physics residency training endorsed by the American Association of Physicists in Medicine, Part I: High-dose-rate remote afterloader brachytherapy.

Brachytherapy·2026

Same author

Cognitive Outcomes After Radiation Therapy for Medulloblastoma: A Voxel-based Analysis.

International journal of radiation oncology, biology, physics·2026

Search research articles

Related Experiment Video

Updated: Jun 6, 2025

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Optimization Processes of Clinical Chelation-Based Radiopharmaceuticals for Pathway-Directed Targeted Radionuclide

Katsumi Tomiyoshi¹, Lydia J Wilson², Firas Mourtada²

¹Shonan Research Institute of Innovative Medicine, Shonan Kamakura General Hospital, Kamakura 247-8533, Japan.

|November 27, 2024

Summary

Targeted radionuclide therapy (TRT) offers precision medicine for cancer, improving tumor control and patient survival. Advances in radiopharmaceuticals, dosimetry, and imaging enhance TRT efficacy and safety.

Keywords:

177Lu 225Ac chelation dosimetry imaging theranostics

More Related Videos

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Published on: February 3, 2015

Preparation and Evaluation of 99mTc-labeled Tridentate Chelates for Pre-targeting Using Bioorthogonal Chemistry

Preparation and Evaluation of 99mTc-labeled Tridentate Chelates for Pre-targeting Using Bioorthogonal Chemistry

Published on: February 4, 2017

Related Experiment Videos

Last Updated: Jun 6, 2025

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Published on: February 3, 2015

Preparation and Evaluation of 99mTc-labeled Tridentate Chelates for Pre-targeting Using Bioorthogonal Chemistry

Preparation and Evaluation of 99mTc-labeled Tridentate Chelates for Pre-targeting Using Bioorthogonal Chemistry

Published on: February 4, 2017

Area of Science:

Nuclear medicine
Radiopharmaceutical chemistry
Oncology

Background:

Targeted radionuclide therapy (TRT) is revolutionizing precision medicine by enhancing tumor control and patient survival.
Theranostic-paired TRT, combined with correlative analyses, shows significant potential for managing malignant diseases.
Chelation chemistry is fundamental for developing effective theranostic radiopharmaceuticals for TRT.

Purpose of the Study:

To review the latest advancements in chelation-based theranostic radiopharmaceuticals for TRT.
To discuss improvements in micro-dosimetry for refining dose-response evaluations.
To highlight the role of SPECT/CT technologies and cytogenetic analyses in TRT.

Main Methods:

Review of current diagnostic (e.g., ⁶⁸Ga, ^99mTc) and therapeutic (e.g., ¹⁷⁷Lu, ²²⁵Ac) radionuclides for TRT.
Analysis of chelation chemistry challenges, including radionuclide production and daughter radionuclide toxicity.
Exploration of micro-dosimetry modeling and SPECT/CT technologies for treatment monitoring.

Main Results:

¹⁷⁷Lu and ²²⁵Ac are promising for beta and alpha TRT, respectively, due to favorable properties for clinical use.
Challenges remain in optimizing radionuclide production, ensuring chelation stability, and refining micro-dosimetry.
Current TRT delivery relies on empirical activity levels, leading to variable outcomes and toxicities.

Conclusions:

Optimizing chelation chemistry and micro-dosimetry is crucial for advancing theranostic radiopharmaceuticals.
Enhanced imaging and correlative analyses are essential for personalized TRT and improved patient outcomes.
Further research is needed to overcome challenges in radionuclide production and minimize treatment-related toxicities.